Peptide Reference
Liraglutide
Liraglutide
The first GLP-1 receptor agonist approved for both type 2 diabetes (Victoza) and weight management (Saxenda). Requires daily injection.
Status
approved
Category
weight loss
Typical cost
$900-1200/month (brand)
Mechanism
Activates GLP-1 receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, delay gastric emptying, and reduce appetite. Same mechanism as other GLP-1s but with shorter duration requiring daily dosing.
Potential benefits
- Weight loss 8-10%
- Improved glycemic control
- Cardiovascular protection
- Reduced appetite
- Proven long-term safety
Reported side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Injection site reactions
- Daily injection burden
Common dosing references
subcutaneous
0.6-3.0mg · Daily
Ongoing
Research notes
SCALE trial - Liraglutide for obesity
2015
Average 8% weight loss at 56 weeks with 3.0mg dose
LEADER trial - Cardiovascular outcomes
2016
Reduced cardiovascular events in type 2 diabetes patients
Regulatory and sourcing notes
FDA-approved (Victoza for diabetes, Saxenda for weight). Available by prescription.
Prescription required. Daily injection vs weekly for semaglutide. Good for those preferring daily routine.
Find peptide-aware clinics
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.
Related peptides